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Objectives:To investigate the effect of dexamethasone on triggering receptor expressed
on myeloid cells-1 (TREM-1).
Methods:Wild-type and tumor necrosis factor (TNF−/−) mice were pre-treated with saline,
dexamethasone, or hydrocortisone and exposed to a lethal infection of Pseudomonas
aeruginosa. Mortality andTREM-1 on neutrophil membranes was measured after sacrifice.
U937 human monocytic cells were stimulated with lipopolysaccharide (LPS) or heat-killed
P. aeruginosa without or with dexamethasone or hydrocortisone, and cell-surface TREM-1
and solubleTREM-1 (sTREM-1) were quantified. Expression ofTREM-1 and sTREM-1 was
also studied in LPS-stimulated U937 cells incubated in the absence or presence of TNFα
or anti-TNFα antibody.
Results:Pre-treatment with dexamethasone, but not hydrocortisone, prolonged animal sur-
vival. Mice pre-treated with dexamethasone showed decreased expression of TREM-1 on
neutrophils. In U937 cells, LPS or heat-killed P. aeruginosa induced the expression ofTREM-
1 and the release of sTREM-1. U937TREM-1 and sTREM-1 were decreased upon addition
of dexamethasone but not hydrocortisone.The suppressive effect of dexamethasone was
enhanced in the presence of exogenous TNFα and lost in the presence of anti-TNFα anti-
body. In TNF−/− mice, dexamethasone suppression of mortality and TREM-1 neutrophil
expression was lost. Gene expression ofTREM-1 in U937 monocytes was decreased after
treatment with dexamethasone.
Conclusion: TREM-1/sTREM-1 is a novel site of action of dexamethasone. This action is
associated with down-regulation of gene expression and is mediated by TNFα.
Keywords:TREM-1,TNFα, monocytes, Pseudomonas aeruginosa, dexamethasone
INTRODUCTION
Triggering receptor expressed on myeloid cells-1 (TREM-1) is
a transmembrane receptor that is expressed on the membrane
of cells of myeloid origin, notably neutrophils and monocytes.
TREM-1 stimulation leads to production of pro-inflammatory
cytokines, including tumor necrosis factor-alpha (TNFα) and
interleukin (IL)-8. The ligand for TREM-1 has not yet been recog-
nized although it is known that stimulation of myeloid cells with
bacterial lipopolysaccharide (LPS) up-regulates TREM-1 expres-
sion (1). TREM-1 is also shed in the systemic circulation from
cell membranes and the soluble receptor, sTREM-1, behaves as an
anti-inflammatory mediator (2).
Current evidence suggests that TREM-1/sTREM-1 may be an
important player in the pathogenesis of sepsis. TREM-1 activity
is thought to be pro-inflammatory and expression of TREM-1 is
elevated on circulating neutrophils in patients with septic shock
(3). sTREM-1 is considered to possess anti-inflammatory activity,
since injection of sTREM-1 protects mice from lethal endotoxic
shock (2). Evidence also suggests an anti-inflammatory role of
sTREM-1 in human sepsis, since it follows the kinetics of anti-
inflammatory cytokines (4). Therefore, TREM-1/sTREM-1 may
be targets for host response modulation in order to offer a survival
benefit for the host.
Corticosteroids are the most widely used suppressors of the
immune response. Corticosteroids with different glucocorticoid
activities have been studied in clinical trials of sepsis with uneven
results. Administration of hydrocortisone in sepsis can decrease
circulating levels of pro-inflammatory cytokines (5, 6). Dexam-
ethasone is the corticosteroid with the greatest anti-inflammatory
activity, and inhibits the ex vivo production of TNFα, IL-6, IL-
8, and IL-12p40 by LPS-stimulated whole blood from patients
with sepsis in a dose-dependent manner (7). However, the
effect of corticosteroids on TREM-1/sTREM-1 has never been
described.
The purpose of this study was to investigate the effect of corti-
costeroids on TREM-1 expression on neutrophils in a lethal mouse
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infection model, and to examine the stimulated expression of
TREM-1 and on sTREM-1 on human myeloid cells in vitro.
MATERIALS AND METHODS
ANIMAL STUDIES
Eighty-six male wild-type C57BL/6 and 32 male homozygous
TNF knockout (TNF−/−) mice weighing 27–29 g were used in
the study. The TNF−/− mice (Alexander Fleming Institute, Vari,
Athens, Greece) were generated on a C57BL/6 genetic background
as described (8). The study received permission from the Vet-
erinary Directorate of the Prefecture of Athens according to
the Greek legislation in conformance to the 160/1991 Council
Directive of the EU. Animals were housed in metal cages and
maintained under specific pathogen-free conditions. Room tem-
perature ranged between 18 and 22˚C, relative humidity between
55 and 65%, and the light/dark cycle was 6:00 a.m./6:00 p.m.
Pseudomonas aeruginosa 2 was isolated from the blood of a
patient with acute pyelonephritis and severe sepsis. The isolate
was multidrug-resistant (MDR) as defined by Clinical and Labo-
ratory Standards Institute (CLSI) criteria. The isolate was stored
in multiple aliquots in skim milk (Oxoid Ltd, London, UK) at
−70˚C. Before each experiment, one aliquot was thawed and cul-
tured on MacConkey agar plates (Becton Dickinson, Cockeysville,
MD, USA). Single colonies were suspended in Mueller–Hinton
broth (Oxoid) and incubated for 12 h at 37˚C in a shaking water
bath. The resulting inoculum was washed three times with 0.9%
NaCl to remove free endotoxin; it was diluted to 1× 107 cfu/ml and
a final volume of 0.15 ml was administered using intraperitoneal
(i.p.) injection under light ether anesthesia.
Animals were randomly assigned into four groups. Two animals
per group were studied per day of experiment.
• Control group (n= 16); wild-type mice injected i.p. with 0.15
of sterile water 1 h before bacterial challenge.
• Dexamethasone group (n= 16); wild-type mice injected i.p.
with 1 mg/kg of dexamethasone (Sigma Co, St. Louis, MO, USA)
dissolved in 0.15 ml sterile water 1 h before bacterial challenge.
The dose of dexamethasone was based on former studies (9).
• Hydrocortisone group 3.6 mg/kg (n= 16); wild-type mice
injected i.p. with 3.6 mg/kg of hydrocortisone (Sigma Co) dis-
solved in 0.15 ml sterile water 1 h before bacterial challenge. The
dose of hydrocortisone was based on former studies (9).
• Hydrocortisone group 36 mg/kg (n= 16); wild-type mice
injected i.p. with 36 mg/kg of hydrocortisone dissolved in
0.15 ml sterile water 1 h before bacterial challenge. The dose of
hydrocortisone was 10 times greater than the dose administered
to mice in the 3.6 mg/kg hydrocortisone group to investigate the
dose-effect of hydrocortisone.
Six animals in each group were sacrificed 6 h after bacterial
challenge. This time point was selected based on preliminary
experiments with 20 mice sacrificed at serial time intervals post
bacterial challenge showing that the peak expression of TREM-
1 on neutrophils was observed 6 h after bacterial challenge (data
not shown). Survival was recorded for the remaining 10 animals
of each group at 6-h intervals for 7 days. Mice were sacrificed by
intramuscular (i.m.) injection of 25 mg/kg ketamine. An abdomi-
nal midline incision was then performed under sterile conditions,
and the intestines were displaced to the left to allow blood sam-
pling by puncture of the lower vena cava with a sterile 26G needle.
Blood was collected into EDTA-coated tubes (Vacutainer, Becton
Dickinson) and centrifuged, and the serum was transferred to a
new tube and stored at −70˚C until assayed. TNFα (R&D Inc,
Minneapolis, MD, USA) was measured in plasma by an enzyme
immunoabsorbent assay (lower limit of detection 15.6 pg/ml).
The sedimented pellets that remained after removal of the serum
were re-suspended in Phosphate Buffered Saline (PBS, pH 7.2,
Biochrom, Berlin, Germany) and the erythrocytes were lysed after
adding 1 mM NH4Cl. Leukocytes were washed three times with
PBS and incubated with mouse anti-TREM-1 antibody PE (R&D
Inc) as described below. Leukocyte subsets were analyzed by the
EPICS XL/MSL flow cytometer (Beckman Coulter, Miami, FL,
USA) after selection for neutrophils by characteristic Forward/Side
scattering. Neutrophils from two uninfected (sham) mice were
used as negative controls. Expression of TREM-1 was given as %
and mean fluorescence intensity (MFI).
In parallel, specimens of liver were aseptically excised and trans-
ferred to separate sterile containers. The livers were weighed and
homogenized in 1 ml of Mueller–Hinton broth and diluted four
consecutive times using serial 1:10 dilutions in 0.9% NaCl. A 0.1 ml
aliquot of each dilution was plated onto MacConkey agar plates.
Plates were incubated for 48 h at 35˚C, and the number of colonies
were counted and multiplied by the corresponding dilution factor.
The results were expressed as log10 cfu/g. The minimum detection
limit was 10 cfu/g.
U937 MONOCYTE EXPERIMENTS
One million cells of the U937 human monocytic cell line were
inoculated into each well of a 12-well plate (final volume 2.4 ml).
The cell culture medium consisted of RPMI 1640 (Biochrom) sup-
plemented with 2 mM of glutamine (Biochrom), 10% Fetal Bovine
Serum (Biochrom), 100 U/ml of penicillin G and 0.1 mg/ml of
streptomycin (Sigma Co). The cultures were incubated at 37˚C
under 5% CO2 for 24 h. Cultures were incubated for 1 h with
medium alone (control), 10µM dexamethasone, or 10µM of
hydrocortisone. Following pre-incubation, cells were stimulated
by adding 10 ng/ml of Escherichia coli O55:B5 (LPS, Sigma) or
1× 106 cfu/ml of heat-killed P. aeruginosa 2. Heat killing was
achieved after incubation for 6 h at 65˚C in a shaking water
bath, and lack of growth was determined following inoculation
in growth media. In separate experiments, U937 cells were pre-
incubated with dexamethasone or hydrocortisone as described
above, in the presence of either TNFα (100 pg/ml, Sigma) or anti-
TNFα antibody (100 pg/ml, Serotec, Marseille, France). Cells were
then stimulated with 10 ng/ml LPS. After 24 h of incubation, the
cultured cells were transferred to a sterile tube, centrifuged, and the
supernatants were transferred to separate tubes and stored until
analysis. sTREM-1 levels were measured in the supernatants by
ELISA (R&D Inc). The cell pellets were diluted with 1 ml of PBS
and 100µl of the cell suspension was transferred to a new tube. Ten
microliters of human anti-TREM-1 monoclonal antibody labeled
with phycoerythrin (PE emission 570 mm, R&D Inc) was added to
the mixture and incubated for 40 min at 4˚C. The cells were then
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washed with PBS pH 7.2 and centrifuged, and the cells were ana-
lyzed by the EPICS XL/MSL flow cytometer. Unstained cells and
antibody isotype controls [cells stained with IgG-PE (Beckman
Coulter)] were used as negative controls. Expression of TREM-1
was expressed as the percent of TREM-1-positive cells compared
to the entire population of leukocytes gated, and MFI was calcu-
lated based on the TREM-1-positive population after subtracting
the background measured in the antibody isotype control cells.
TREM-1 EXPRESSION ANALYSIS
To measure the effect of dexamethasone on expression of
the TREM-1 gene, U937 monocytes were stimulated with
1× 106 cfu/ml of heat-killed P. aeruginosa 2 without or with
10µM dexamethasone for 8 h. After stimulation, the cultured cells
were collected and centrifuged, and the supernatant discarded.
The cell pellets were treated with consecutive treatments of Trizol
(AppliChem, GmbH, Germany) and chloroform, and contami-
nating DNA was removed by treatment for 30 min at 37˚C with
0.04 U/µl of DNAase (Ambion). To produce cDNA, 1.5µg of RNA
was incubated with 0.4 mM of dNTPs (New England BioLabs,
Ipswitch, MA, USA), 1.0 U of RNA-sin (New England BioLabs),
10 mM DTT (New England BioLabs), and 5× reverse transcrip-
tase buffer. In a Mastercycler 5330 (Eppendorf), the RNA was
initially incubated for 10 min at 65˚C. One microunit of reverse
transcriptase (New England BioLabs) was added and the reactions
consecutively incubated at: 10 min at 25˚C; 50 min at 42˚C; and
15 min at 70˚C. Samples without reverse transcriptase were used
as blanks, and cDNA was kept at−80˚C until assayed.
Quantitative PCR was performed in 96-well plates with a iQ5
Real Time PCR Detection System (BioRad Laboratories Inc, USA).
Quantification of TREM-1 mRNA levels was calculated relative
to the housekeeping gene encoding β2-microglobulin. Reactions
were performed in a final volume of 20µl containing 10µl Flu-
ocycleTM II SYBR Master Mix (EuroClone S.p.a-Italy), 7.0µl
PCR-grade water (AppliChem), 1.0µl cDNA, and 1.0µl each of
the 20µM forward and reverse gene-specific primers. The reac-
tions were incubated at 95˚C for 5 min, followed by 40 PCR cycles.
Each cycle consisted of three steps: denaturation (95˚C for 10 s),
annealing (60˚C for 30 s), and extension (75˚C for 30 s). Blanks
were subjected to this protocol as well. Melting curve analyses was
performed for all genes and confirmed the specificity of the PCR
products by the presence of a single peak. PCR products were
visualized on 3% agarose gels and stained with ethidium bromide
(AppliChem, GmbH, Germany). PCR primers were: TREM-1,
sense 5′-TGG TCT TCT CTG TCC TGT TTG-3′; antisense 5′-
ACT CCC TGC CTT TTA CCT C-3; β2-microglobulin, sense
5′-ATG AGT ATG CCT GCC GTG TG-3′; antisense, 5′-CCA AAT
GCG GCA TCT TCA AAC-3′ (10). The number of transcripts was
measured using the PFAFFL equation (11).
STATISTICAL ANALYSIS
Results are presented as means± SE. Comparisons were done
by the Mann–Whitney U test with Bonferroni corrections for
multiple comparisons. Survival was calculated by Kaplan–Meier
analysis; comparisons between groups were performed by the log-
rank test. Percent changes after treatment with dexamethasone
were calculated by the formula 100× [Effect of stimulus− Effect
of stimulus after dexamethasone treatment]/Effect of stimulus,
where stimulus was either LPS or heat-killed P. aeruginosa. Any p
value below 0.05 was considered statistically significant.
RESULTS
DEXAMETHASONE EFFECTS ON MORTALITY AND TREM-1 EXPRESSION
IN MICE
Pre-treatment of C57BL/6 mice with dexamethasone signifi-
cantly prolonged animal survival (Figure 1A) compared to P.
aeruginosa-infected mice treated with water (controls). How-
ever, pre-treatment with hydrocortisone did not affect survival
(data not shown). Compared to control mice that were infected
with P. aeruginosa but not treated with corticosteroids, the per-
cent of circulating neutrophils expressing TREM-1 was decreased
in mice pre-treated with dexamethasone [30% mean reduction,
Figure 1B (p= 0.044)], and the MFI of TREM-1 on TREM-
1-positive cells was also decreased (mean 14.2% reduction,
p= 0.035). However, pre-treatment of mice with any concen-
tration of hydrocortisone did not significantly affect TREM-1
expression (Figures 1B,C) compared to controls. Administration
of dexamethasone decreased serum TNFα (94% mean reduction,
p= 0.005) but did not affect liver bacterial load (Figures 1D,E).
DEXAMETHASONE EFFECT ON STIMULATED U937 CELLS
The human monocytic U937 cell line was utilized to determine
the effects of dexamethasone on TREM-1 expression. Cells were
pre-incubated without (control) or with dexamethasone or hydro-
cortisone prior to stimulation with LPS or heat-killed P. aerugi-
nosa. Compared to control cells, pre-treatment of U937 cells with
dexamethasone prior to LPS stimulation decreased the percent
of TREM-1-positive cells by 5.2% (p= 0.014, Figure 2A), and
dexamethasone pre-treatment reduced the percent of TREM-1-
positive cells stimulated with in heat-killed P. aeruginosa by 8.2%
(not significant, Figure 2D). A similar reduction in TREM-1 MFI
was observed in LPS-stimulated cells compared to control cells
(Figure 2B, 41.3% mean reduction, p= 0.005). There were no
significant changes in hydrocortisone-treated cells compared to
controls (Figure 2E).
sTREM-1 levels decreased by 51.7% in dexamethasone-treated
cells that were stimulated with LPS compared to control cells
(Figure 2C, p= 0.011). Similarly, sTREM-1 levels decreased by
55.5% in dexamethasone-treated cells that were stimulated with
P. aeruginosa (Figure 2F, p= 0.041). No effect of hydrocortisone
was observed on sTREM-1 levels compared to control cells.
ROLE OF TNFα ON DEXAMETHASONE SUPPRESSION OF TREM-1 AND
sTREM-1
Since dexamethasone inhibits release of TNFα from whole blood
of patients with sepsis (7), we investigated the role of TNFα on the
observed effect of dexamethasone inhibition of TREM-1/sTREM-
1 expression. Addition of TNFα to U937 cells increased the percent
of TREM-1-positive cells stimulated with LPS compared to LPS
alone (compare LPS bars in Figures 2A and 3A). Addition of dex-
amethasone completely suppressed LPS-stimulated production
of TREM-1, similar to levels observed for untreated cell con-
trols (Figure 3A, p< 0.0001). Similar dexamethasone suppressive
effects were observed for TREM-1 MFI (Figure 3B,p= 0.001), and
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FIGURE 1 | Dexamethasone is a modulator ofTREM-1 expression on
mouse neutrophils. Wild-type male C57BL6 mice were challenged by a
multidrug-resistant isolate of P. aeruginosa. Ten mice were pre-treated 1 h
before challenge either with saline (control group, CON), dexamethasone
(DEX), 3.6 mg/kg hydrocortisone (HYD3.6), or 36 mg/kg of hydrocortisone
(HYD36). (A) Represents survival of the control group (solid line), and
dexamethasone-treated animals (dashed line). (B,C) Shows the expression
of TREM-1 on circulating neutrophils at animal sacrifice, (D) shows serum
concentrations of TNFα at animal sacrifice, and (E) shows liver bacterial
loads. Results from (B–E) refer to six mice per group. Data in uninfected
mice are also provided [Sham in (B,C)]. Data for TREM-1 are shown as
percent of neutrophils expressing TREM-1 (B) or expressed as TREM-1 MFI
for neutrophils (C). P values indicate significant differences compared to
control.
sTREM-1 levels (Figure 3C, p= 0.029) compared to the LPS-only
controls.
To separately confirm the affects of TNFα on TREM-1 expres-
sion, U937 cells were incubated with an anti-TNFα antibody.
Blockade of TNFα activity by the anti-TNFα antibody completely
abolished the dexamethasone-dependent suppression of TREM-1
and sTREM-1 (Figures 3D–F).
AFFECT OF DEXAMETHASONE ON P. AERUGINOSA-INDUCED
MORTALITY AND TREM-1 EXPRESSION IN TNF−/− MICE
In order to further understand the significance of TNFα for the
suppressive effect of dexamethasone on TREM-1 expression, ani-
mal experiments were conducted in mice deficient for TNFα.
TNF−/−mice were pre-treated with either saline (control) or dex-
amethasone prior to infection with P. aeruginosa. As shown in
Figure 4A, pre-treatment with dexamethasone did not offer any
significant survival benefit. Expression of TREM-1 on circulating
neutrophils was not significantly decreased in the dexamethasone-
treated mice compared to the control mice (Figures 4B,C).
EFFECT OF DEXAMETHASONE ON STIMULATED TREM-1 GENE
EXPRESSION IN U937 CELLS
To examine if the dexamethasone mechanism of action is medi-
ated through an affect on gene expression, U937 monocytes were
stimulated with heat-killed P. aeruginosa. Treatment of cells with
dexamethasone significantly decreased the number of TREM-
1 copies (Figure 5) compared to stimulated cells (92.5% mean
reduction, p= 0.021).
DISCUSSION
Our results suggest a new target of action of dexamethasone. Dex-
amethasone, but not hydrocortisone, down-regulates expression
of the inflammation-associated cell-surface receptor TREM-1 on
mouse neutrophils and human U937 monocytic cells following
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FIGURE 2 | Dexamethasone is a modulator ofTREM-1 expression in
human U937 monocytic cells. Human U937 monocytic cells were
stimulated either with E. coli lipopolysaccharide (LPS) or with heat-killed
Pseudomonas aeruginosa 2 (PS). U937 cells were treated for 1 h with
dexamethasone (DEX) or hydrocortisone (HYD) prior to stimulation.
(A,B) Show TREM-1 expression after stimulation with LPS, and (C) shows
sTREM-1 production after stimulation with LPS. (D,E) Show TREM-1
expression after stimulation with PS, and (F) shows sTREM-1 production
after stimulation with PS. DEX/HYD represent unstimulated cells treated
only with DEX or HYD, and the results are averaged. Data for TREM-1 are
shown as percent of U937 cells expressing TREM-1 (A,D), or as TREM-1
MFI for U937 cells (B,E). Results from six experiments are shown. P
values indicate significant differences compared to LPS or PS-treated
cells.
stimulation. Dexamethasone also reduces production of stimu-
lated production of sTREM-1. We show that dexamethasone inhi-
bition of stimulated TREM-1 is associated with reduced TREM-
1 gene expression. Finally, we demonstrate that dexamethasone
suppression of TREM-1 is dependent on TNFα.
Since TREM-1 expression on cell surfaces has been associated
with septic shock in humans (1) and sTREM-1 protects mice
from endotoxic shock (2), TREM-1 modulation may have poten-
tial as a sepsis therapy. To this end, the presented findings sug-
gest that glucocorticoids may modulate TREM-1. Glucocorticoids
may act in septic shock to reverse relative adrenal insufficiency
(12, 13). However, corticosteroids are potent anti-inflammatory
drugs, and in acute disease settings, may down-regulate the pro-
duction of monocytic pro-inflammatory cytokines (7). A rela-
tionship between corticosteroid administration and sepsis was
suggested when the administration of low-doses of hydrocorti-
sone to septic patients significantly reduced circulating levels of
IL-6 and of IL-8. IL-6 and IL-8 levels were restored to the former
baseline values after the withdrawal of hydrocortisone (5, 6).
Recent evidence generated in a double-blind randomized
trial in patients with community-acquired pneumonia suggested
a possible clinical role for a dexamethasone-mediated anti-
inflammatory effect. Patients were treated intravenously with
either placebo or with 5 mg dexamethasone for 4 days. Results
from this study indicated a significant reduction of the median
length of hospital stay from 7.5 days in the placebo arm to
6.5 days in the dexamethasone arm (14). Two days after the start
of treatment, circulating levels of TNFα, IL-6, IL-8, and mono-
cyte chemotactic protein (MCP-1) were decreased compared with
placebo-treated patients. The effect of dexamethasone on circu-
lating TNFα levels was more prominent within patients infected
by Streptococcus pneumoniae (15).
The findings of the present study suggest another site
of action of dexamethasone that has not previously been
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FIGURE 3 | Dexamethasone modulatesTREM-1 expression in human
U937 monocytic cells in the presence ofTNFα or anti-TNFα antibody.
Human U937 monocytic cells were stimulated with LPS, and expression
of TREM-1 on cell membranes and concentrations of sTREM-1 in
supernatants were measured after 24 h of incubation. Cells were
pre-incubated prior to stimulation for 1 h without or with dexamethasone
(DEX) in the presence of either TNFα or anti-TNF blocking antibody.
(A,B) Show TREM-1 expression after stimulation with LPS in the presence
of TNFα, and (C) shows sTREM-1 production after stimulation with LPS in
the presence of TNFα. (D,E) Show TREM-1 expression after stimulation
with LPS in the presence of anti-TNFα, and (F) shows modulation of
sTREM-1 production after stimulation with LPS in the presence of
anti-TNFα. CON in (A–C) represents unstimulated cells treated in medium
alone; CON in (D–F) represent unstimulated cells treated in medium
alone. Results from six experiments are shown. Data for TREM-1 are
shown as percent of U937 cells expressing TREM-1 (A,D), or as TREM-1
MFI for U937 cells (B,E). P values indicate significant differences
compared to LPS-treated cells.
described: TREM-1/sTREM-1. In animal experiments, P. aerug-
inosa was selected for animal challenge since this species is often
MDR and a frequent cause for hospital-acquired sepsis. Available
antimicrobials are limited for MDRP. aeruginosa and management
of P. aeruginosa infections can be challenging. As a consequence,
adjuvant therapies targeting pathogenesis are welcomed. Experi-
mental infection by MDR P. aeruginosa led to early death, and pre-
treatment with dexamethasone prolonged survival. The dexam-
ethasone affect on survival was accompanied by down-regulation
of the expression of TREM-1 on neutrophils. A similar effect
was not found for hydrocortisone even when the dose used for
pre-treatment was increased 10 times. The greater glucocorticoid
biological activity of dexamethasone compared to hydrocortisone
may be part of the explanation. The effect of dexamethasone could
possibly be extrapolated to infections by other Gram-negative
bacteria since down-regulation of TREM-1/sTREM-1 was also
shown when LPS was used to stimulate U937 cells. Our stud-
ies suggest that dexamethasone-mediated protection observed in
the mouse experiments is mediated through down-regulation of
TREM-1 gene expression. Reduced TREM-1 gene expression also
likely explains reduced levels of sTREM-1. The presence of a pro-
tease that cleaves cell membrane TREM-1 and releases sTREM-1
has been described on myeloid cells (2). However, we believe it
is unlikely that dexamethasone-mediated reduction of sTREM-1
levels results from protease inhibition since cell-surface TREM-1
levels were similarly reduced.
We observed that dexamethasone requires the presence of
TNFα to manifest the effect on TREM-1/sTREM-1. P. aeruginosa
stimulated significant production of TNFα in the mouse model.
Further, in studies where TNFα was reduced (either through
antibody blockade or through the use of TNF−/− mice), the
suppressive effect of dexamethasone on TREM-1 expression was
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FIGURE 4 | Dexamethasone is not a modulator ofTREM-1 expression in
TNF−/− mice. TNF−/− male mice were challenged by a multidrug-resistant
isolate of P. aeruginosa. Mice were pre-treated 1 h before challenge with
either saline (CON) or dexamethasone (DEX). In (A), survival of 10 control
mice (solid line) and 10 DEX mice (dashed line) is shown. In (B,C), expression
of TREM-1 on neutrophils at sacrifice performed 6 h after bacterial challenge
(six mice per group) is shown. Results from sham-treated mice (Sham, no
infection with P. aeruginosa) are also provided. Data for TREM-1 are shown as
percent of neutrophils expressing TREM-1 (B) or expressed as TREM-1 MFI
for neutrophils (C).
FIGURE 5 | Dexamethasone down-regulates gene expression of
TREM-1. Human U937 monocytic cells were stimulated with heat-killed
Pseudomonas aeruginosa (PS). Cells were pre-treated for 1 h in the
absence or presence of dexamethasone (DEX) prior to stimulation. Results
from four experiments are shown. P value indicates significant difference
compared with PS-treated cells.
lost. The exact relationship between TREM-1/sTREM-1, dexam-
ethasone, and TNFα cannot be fully elucidated with the current
data. Since the TNF and TREM-1 genes are located on different
chromosomes, down-regulation of TREM-1 by dexamethasone
may require parallel down-regulation of TNF (16). A hypothetical
mechanism is shown in Figure 6. Alternatively, dexamethasone
effect on TREM-1 gene expression may be dependent on TNF
signaling effects.
Two main limitations of this study should be addressed.
First, we did not perform dose response experiments with dex-
amethasone. We do not believe that these experiments were
necessary since the applied dose of dexamethasone for both
in vitro and in vivo studies correspond to reported serum lev-
els (9). Second, we did not examine TREM-1 protein levels using
Western blot analysis. However, we feel that reporting TREM-1
expression on cells both as percentage and MFI, and measur-
ing of sTREM-1 levels in supernatants adequately supports our
conclusions.
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FIGURE 6 | Model for the mechanism of action of dexamethasone.
After infection with Gram-negative bacteria like P. aeruginosa, endotoxin
(LPS) induces production of the TREM-1 receptor. Membrane-bound
TREM-1 can be proteolytically processed, resulting in release of
sTREM-1 into the extracellular space. Dexamethasone (DEX)
suppresses the activity of TNFα, and since TNFα may have a positive
effect onTREM-1 expression, DEX indirectly inhibits TREM-1
expression. We speculate that DEX may also directly down-regulate
TREM-1 gene expression, resulting in reduced production of
membrane-bound TREM-1 and sTREM-1.
Recent findings using mouse sepsis models underscore the
possible importance of inhibition of the TREM-1 ligand (as yet
undefined) as a strategy for the management of sepsis. In these
studies, sepsis was induced after challenge withBacillus pyocyaneus
and P. aeruginosa (17, 18). Administration of a TREM-1 fusion
protein either as pre-treatment 1 h before bacterial challenge or
1 h after bacterial challenge prolonged animal survival. Circulating
levels of TNFα, IL-1β, IL-6, and MCP-1 were decreased, whereas
tissue bacterial load remained unchanged. Taken together, the
findings of these animal studies (17, 18) and results of the present
study suggest that modulation of TREM-1 is a possible thera-
peutic target for acute infection settings. Possible interventions
include administration of dexamethasone or a TREM-1 fusion
protein. Furthermore, in a recent study by our group, gene tran-
scripts of TREM-1 and of TNF were measured in circulating
monocytes from 13 patients with severe sepsis and from seven
patients with uncomplicated sepsis within the first 24 h diagnosis.
Gene expression of TNF in severe sepsis was down-regulated as
expected due to the immunoparalysis of circulating monocytes.
However, gene expression of TREM-1 was up-regulated in cir-
culating monocytes of patients experiencing severe sepsis (10).
These clinical observations along with the described effect of
dexamethasone on down-regulation of TREM-1 gene expression
suggest the possibility of administration of dexamethasone in the
septic host.
The presented results indicate TREM-1/sTREM-1 as a novel
site of action for dexamethasone modulation. Dexamethasone
decreases expression of TREM-1 on myeloid cells, and this
phenomenon is related to down-regulation of gene expression
and is modulated by TNFα. This action of dexamethasone was
accompanied by significant prolongation of survival in experi-
mental infection by P. aeruginosa.
ACKNOWLEDGMENTS
This work was supported in part by the Federal Ministry of
Education and Research (BMBF), Germany, FKZ: 01EO1002.
REFERENCES
1. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be
triggered by TREM-1, a novel receptor expressed on neutrophils andmonocytes.
J Immunol (2000) 164:4991–5.
2. Gibot S, Kolopp Sarda MN, Béné MC, Bollaert PE, Lozniewski A, Mory F, et al.
A soluble form of the triggering receptor expressed on myeloid cells-1 modu-
lates the inflammatory response in murine sepsis. J ExpMed (2004) 11:1419–26.
doi:10.1084/jem.20040708
3. Gibot S, Kollop-Sarda MN, Béné M, Cravoisy A, Levy B, Faure GC, et al.
Plasma level of a triggering receptor expressed onmyeloid cells-1: its diagnostic
accuracy in patients with suspected sepsis. Ann Intern Med (2004) 141:9–15.
doi:10.7326/0003-4819-141-1-200407060-00009
4. Giamarellos-Bourboulis EJ, Zakynthinos S, Baziaka F, Papadomichelakis E,
Virtzili S, Koutoukas P, et al. Soluble triggering receptor expressed on myeloid
cells-1 as an antiinflammatory mediator in sepsis. Intensive Care Med (2006)
32:237–43. doi:10.1007/s00134-005-0017-1
5. Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, et al.
Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic
shock: a double-blind, randomized, placebo-controlled, crossover study. Am J
Respir Crit Care Med (2003) 167:512–20. doi:10.1164/rccm.200205-446OC
6. Oppert M, Schindler R, Husung C. Low-dose hydrocortisone improves shock
reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit
Care Med (2005) 33:2457–64. doi:10.1097/01.CCM.0000186370.78639.23
7. Giamarellos-Bourboulis EJ, Dimopoulou I, Kotanidou A, Livaditi O, Pelekanou
A, Tsagarakis S, et al. Ex-vivo effect of dexamethasone on cytokine production
Frontiers in Public Health | Infectious Diseases November 2013 | Volume 1 | Article 50 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mihailidou et al. Effect of dexamethasone on TREM-1
from whole blood of septic patients: correlation with disease severity. Cytokine
(2010) 49:89–94. doi:10.1016/j.cyto.2009.08.016
8. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflamma-
tory response in TNFα-deficient mice: a critical requirement for TNFα in the
formation of primary B cell follicles, follicular dendritic cell networks and ger-
minal centers, and in the maturation of the humoral immune response. J Exp
Med (1996) 184:1397–411. doi:10.1084/jem.184.4.1397
9. Nin N, Penuelas O, de Paula M, Lorente JA, Fernandez-Segoviano P, Estaben A.
Ventilation-induced lung injury in rats is associated with organ injury and sys-
temic inflammation that is attenuated by dexamethasone. Crit CareMed (2004)
34:1093–8.
10. Dimopoulou I, Pelekanou A, Mavrou I, Savva A, Tzanela M, Kotsaki A, et al.
Early serum levels of soluble triggering receptor expressed on myeloid cells-
1: correlation with monocyte gene expression. J Crit Care (2012) 27:294–300.
doi:10.1016/j.jcrc.2011.06.013
11. Hunt M. Real-Time PCR. (2010). Available from: http://pathmicro.med.sc.edu/
pcr/realtime-home.htm
12. Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM,
et al. Effect of treatment with low doses of hydrocortisone and fludrocorti-
sone on mortality in patients with septic shock. JAMA (2002) 288:862–71.
doi:10.1001/jama.288.7.862
13. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Sur-
viving sepsis campaign: international guidelines for management of severe sep-
sis and septic shock: 2008. Intensive Care Med (2008) 34:17–60. doi:10.1007/
s00134-008-1040-9
14. Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers G, van
Velzen-Bald H, et al. Dexamethasone and length of hospital stay in patients
with community-acquired pneumonia: a randomized, double-blind, placebo-
controlled trial. Lancet (2011) 377:2023–30. doi:10.1016/S0140-6736(11)
60607-7
15. Remmelts HHF, Meijvis SCA, Biesma DH, van Helzen-Blad H, Voorn GP, Grut-
ters JC, et al. Dexamethasone downregulates the systemic cytokine response in
patients with community-acquired pneumonia. Clin Vaccine Immunol (2012)
19:1532–8. doi:10.1128/CVI.00423-12
16. Necela BM, Cidlowski JA. Mechanisms of glucocorticoid receptor action in
noninflammatory and inflammatory cells. Proc Am Thor Soc (2004) 1:239–46.
doi:10.1513/pats.200402-005MS
17. Tong J, Lu ZC, Wang DX. Azithromycin acts as an immunomodulatory agent
to suppress the expression of TREM-1 in Bacillus pyocyaneus-induced sepsis.
Immunol Lett (2011) 138:137–43. doi:10.1016/j.imlet.2011.04.001
18. Wang F, Liu S, Wu S, Zhu Q, Ou G, Liu C, et al. Blocking TREM-1 signaling
prolongs survival of mice with Pseudomonas aeruginosa induced sepsis. Cell
Immunol (2012) 272:251–8. doi:10.1016/j.cellimm.2011.10.006
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 09 January 2013; paper pending published: 31 January 2013; accepted: 24
April 2013; published online: 14 November 2013.
Citation: Mihailidou I, Pelekanou A, Pistiki A, Spyridaki A, Tzepi I-M, Damoraki G
and Giamarellos-Bourboulis EJ (2013) Dexamethasone down-regulates expression of
triggering receptor expressed on myeloid cells-1: evidence for a TNFα-related effect.
Front. Public Health 1:50. doi: 10.3389/fpubh.2013.00050
This article was submitted to Infectious Diseases, a section of the journal Frontiers in
Public Health.
Copyright © 2013 Mihailidou, Pelekanou, Pistiki, Spyridaki, Tzepi, Damoraki and
Giamarellos-Bourboulis. This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
www.frontiersin.org November 2013 | Volume 1 | Article 50 | 9
